tiprankstipranks
Annovis Bio’s Alzheimer’s Drug Buntanetap Shows Promise
Company Announcements

Annovis Bio’s Alzheimer’s Drug Buntanetap Shows Promise

Pick the best stocks and maximize your portfolio:

The latest announcement is out from Annovis Bio (ANVS).

Annovis Bio, Inc. has announced positive results for its leading Alzheimer’s drug, Buntanetap, demonstrating significant efficacy and safety in patients regardless of their genetic risk from Apolipoprotein E4. Following the announcement, the company detailed the drug’s prospects and future plans in a post-market webcast.

See more insights into ANVS stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAnnovis Bio Advances Alzheimer’s and Parkinson’s Drug Trials
TipRanks Auto-Generated NewsdeskAnnovis Bio Appoints William Fricker as Interim CFO
TheFlyAnnovis sees cash runway for Phase 3 preparatory studies, entering AD study
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App